APA

Burtness B., Belker M., Stoltz M., Peccerillo K. M., Lamb L. A., Chmael S. E., McKeon A., Clark M. B., Winship J., Marsh J. C., Pizzorno G. & DeVita V. T. (20010301). A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. : Cancer journal (Sudbury, Mass.).

Chicago

Burtness B, Belker M, Stoltz M, Peccerillo K M, Lamb L A, Chmael S E, McKeon A, Clark M B, Winship J, Marsh J C, Pizzorno G and DeVita V T. 20010301. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. : Cancer journal (Sudbury, Mass.).

Harvard

Burtness B., Belker M., Stoltz M., Peccerillo K. M., Lamb L. A., Chmael S. E., McKeon A., Clark M. B., Winship J., Marsh J. C., Pizzorno G. and DeVita V. T. (20010301). A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. : Cancer journal (Sudbury, Mass.).

MLA

Burtness B, Belker M, Stoltz M, Peccerillo K M, Lamb L A, Chmael S E, McKeon A, Clark M B, Winship J, Marsh J C, Pizzorno G and DeVita V T. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. : Cancer journal (Sudbury, Mass.). 20010301.